window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Precision Medicine

  • Artificial Intelligence,Clinical Development,Genomics and sequencing,Obesity,Precision medicine,Technology and platforms

    23andMe study links genetics to GLP-1 weight loss outcomes and side effects

    This Nature-published study from the 23andMe Research Institute identifies genetic [...]

    April 9, 2026
  • Central Nervous System,Clinical Development,Clinical Trials,Drug Development,FDA,Pharmaceuticals and therapeutics,Precision medicine,Research & Development

    Alto Neuroscience completes Phase 2 enrollment for ALTO-101 in cognitive impairment associated with schizophrenia

    Alto Neuroscience has completed patient enrollment in its Phase 2 [...]

    February 13, 2026
  • Healthcare leadership,Market Access & Commercialization,Oncology,Patient Centricity,Precision medicine

    UK national cancer plan aims to boost survival and cut inequalities in diagnosis and treatment

    The UK Government this World Cancer Day has published its [...]

    February 4, 2026
  • Clinical studies,Drug Development,Oncology,Precision medicine,Research & Development

    Nine-gene signature linked to lapatinib resistance in HER2-positive breast cancer

    Researchers at City St George’s, University of London have identified [...]

    January 29, 2026
  • Artificial Intelligence,Biotech,Drug Development,Pharmaceuticals and therapeutics,Precision medicine,Research & Development,Technology and platforms

    CytoReason unveils LINA, AI agent accelerated by NVIDIA for pharma R&D

    CytoReason has unveiled LINA, an AI agent designed to support [...]

    January 13, 2026
  • Biotech,Cell & Gene Therapy,Genetic Diseases,Genomics and sequencing,Rare Diseases,Research & Development,Technology and platforms

    PacBio HiFi adopted to study sudden unexplained death in childhood and advance precision therapies for rare diseases

    PacBio is supporting two research initiatives that use its HiFi [...]

    January 13, 2026
  • Clinical Trials,Immunology,Neurosciences,Precision medicine

    AC Immune interim Phase 2 data suggest ACI-7104.056 may slow Parkinson’s disease progression

      AC Immune SA has reported positive interim results from [...]

    December 11, 2025
  • Clinical Trials,Oncology,Research & Development

    €1 million investment for BiPER Therapeutics to launch BPR001-615 BiP inhibitor trial

    BiPER Therapeutics has raised €1 million ($1.16M) to support the [...]

    December 2, 2025
  • Artificial Intelligence,Genomics and sequencing,Research & Development

    Sheba, Mount Sinai and NVIDIA launch AI collaboration to decode unexplored regions of the human genome

    ARC Innovation at Sheba Medical Center and the Icahn School [...]

    November 18, 2025
  • Oncology,Pharmaceuticals and therapeutics,Research & Development

    UK nuclear materials to power new precision cancer therapies

    The UK is launching a major programme to convert used [...]

    November 18, 2025
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Chemify founder publishes three papers on programmable chemistry and automated drug discovery
    Categories: Artificial Intelligence, Drug discovery, Research & Development, Technology and platforms
  • European liver experts highlight rising MASLD burden at EASL symposium in Budapest
    Categories: Clinical studies, Gastroenterology, Healthcare leadership, Liver disease, Metabolic Diseases
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top